Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 565

1.

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.

Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, Cybulski C, Wisniowski R, Godlewski D, Lubinski J, Narod SA.

Breast Cancer Res Treat. 2014 Aug 17. [Epub ahead of print]

PMID:
25129345
[PubMed - as supplied by publisher]
2.

Prostate Cancer in a Man with a BRCA2 Mutation and a Personal History of Bilateral Breast Cancer.

Singer CF, Rappaport-Fuerhauser C, Sopik V, Narod SA.

Clin Genet. 2014 Aug 12. doi: 10.1111/cge.12478. [Epub ahead of print]

PMID:
25112434
[PubMed - as supplied by publisher]
3.

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.

Akbari MR, Wallis CJ, Toi A, Trachtenberg J, Sun P, Narod SA, Nam RK.

Br J Cancer. 2014 Aug 7. doi: 10.1038/bjc.2014.428. [Epub ahead of print]

PMID:
25101567
[PubMed - as supplied by publisher]
4.

Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.

Giannakeas V, Lubinski J, Gronwald J, Moller P, Armel S, Lynch HT, Foulkes WD, Kim-Sing C, Singer C, Neuhausen SL, Friedman E, Tung N, Senter L, Sun P, Narod SA.

Breast Cancer Res Treat. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1.

PMID:
25082516
[PubMed - in process]
5.

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Timorek A, Menon U, Gentry-Maharaj A, Gayther SA, Ramus SJ, Narod SA, Risch HA, McLaughlin JR, Siddiqui N, Glasspool R, Paul J, Carty K, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Kiemeney LA, Massuger LF, van Altena AM, Aben KK, Olson SH, Orlow I, Cramer DW, Levine DA, Bisogna M, Giles GG, Southey MC, Bruinsma F, Kjaer SK, Høgdall E, Jensen A, Høgdall CK, Lundvall L, Engelholm SA, Heitz F, du Bois A, Harter P, Schwaab I, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Thompson PJ, Lurie G, Wilkens LR, Lambrechts D, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Beesley J; AOCS Study Group/ACS Investigators, Fasching PA, Beckmann MW, Hein A, Ekici AB, Doherty JA, Wu AH, Pearce CL, Pike MC, Stram D, Chang-Claude J, Rudolph A, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Bogdanova N, Antonenkova N, Odunsi K, Edwards RP, Kelley JL, Modugno F, Ness RB, Karlan BY, Walsh C, Lester J, Orsulic S, Fridley BL, Vierkant RA, Cunningham JM, Wu X, Lu K, Liang D, Hildebrandt MA, Weber RP, Iversen ES, Tworoger SS, Poole EM, Salvesen HB, Krakstad C, Bjorge L, Tangen IL, Pejovic T, Bean Y, Kellar M, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Campbell IG, Eccles D, Whittemore AS, Sieh W, Rothstein JH, Anton-Culver H, Ziogas A, Phelan CM, Moysich KB, Goode EL, Schildkraut JM, Berchuck A, Pharoah PD, Sellers TA, Brooks-Wilson A, Cook LS, Le ND.

Mol Nutr Food Res. 2014 Jul 28. doi: 10.1002/mnfr.201400068. [Epub ahead of print]

PMID:
25066213
[PubMed - as supplied by publisher]
6.

Strategies for Recruitment of Relatives of BRCA Mutation Carriers to a Genetic Testing Program in the Bahamas.

Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA.

Clin Genet. 2014 Jul 25. doi: 10.1111/cge.12468. [Epub ahead of print]

PMID:
25060751
[PubMed - as supplied by publisher]
7.

Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States.

Hernandez RK, Quach D, Wade SW, Pirolli M, Quigley J, Narod SA, Liede A.

Breast Cancer Res Treat. 2014 Aug;146(3):637-46. doi: 10.1007/s10549-014-3052-1. Epub 2014 Jul 23.

PMID:
25053278
[PubMed - in process]
8.

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.

Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, Segev Y, Sun P, Narod SA.

Gynecol Oncol. 2014 Jul 12. pii: S0090-8258(14)01079-8. doi: 10.1016/j.ygyno.2014.07.004. [Epub ahead of print]

PMID:
25026637
[PubMed - as supplied by publisher]
9.

BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.

Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA.

Br J Cancer. 2014 Jul 15. doi: 10.1038/bjc.2014.391. [Epub ahead of print]

PMID:
25025957
[PubMed - as supplied by publisher]
10.

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21.

PMID:
24951267
[PubMed - in process]
11.

Multiple primary cancers as a guide to heritability.

Cybulski C, Nazarali S, Narod SA.

Int J Cancer. 2014 Oct 15;135(8):1756-63. doi: 10.1002/ijc.28988. Epub 2014 Jun 19.

PMID:
24945890
[PubMed - in process]
12.

Factors associated with breast cancer mortality after local recurrence.

Dent R, Valentini A, Hanna W, Rawlinson E, Rakovitch E, Sun P, Narod SA.

Curr Oncol. 2014 Jun;21(3):e418-25. doi: 10.3747/co.21.1563.

PMID:
24940101
[PubMed]
Free PMC Article
13.

A comparison of the risks of in-breast recurrence after a diagnosis of dcis or early invasive breast cancer.

Narod SA, Rakovitch E.

Curr Oncol. 2014 Jun;21(3):119-24. doi: 10.3747/co.21.1892.

PMID:
24940092
[PubMed]
Free PMC Article
14.

Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?

Vyarvelska I, Rosen B, Narod SA.

Gynecol Oncol. 2014 Aug;134(2):219-21. doi: 10.1016/j.ygyno.2014.05.020. Epub 2014 Jun 2. No abstract available.

PMID:
24887353
[PubMed - in process]
15.

Genetics of endometrial cancer.

Shai A, Segev Y, Narod SA.

Fam Cancer. 2014 May 17. [Epub ahead of print]

PMID:
24838932
[PubMed - as supplied by publisher]
16.

BRCA1 founder mutations compared to ovarian cancer in Belarus.

Savanevich A, Oszurek O, Lubiński J, Cybulski C, Dębniak T, Narod SA, Gronwald J.

Fam Cancer. 2014 Apr 27. [Epub ahead of print]

PMID:
24770866
[PubMed - as supplied by publisher]
17.

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

Narod SA, Tung N, Lubinski J, Huzarski T, Robson M, Lynch HT, Neuhausen SL, Ghadirian P, Kim-Sing C, Sun P, Foulkes WD; Hereditary Breast Cancer Clinical Study Group.

Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.

PMID:
24764694
[PubMed]
Free PMC Article
18.

Risk factors for ovarian cancers with and without microsatellite instability.

Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J.

Int J Gynecol Cancer. 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134.

PMID:
24755492
[PubMed - in process]
19.

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.

Hernández JE, Llacuachaqui M, Palacio GV, Figueroa JD, Madrid J, Lema M, Royer R, Li S, Larson G, Weitzel JN, Narod SA.

Hered Cancer Clin Pract. 2014 Apr 17;12(1):11. doi: 10.1186/1897-4287-12-11. eCollection 2014.

PMID:
24742220
[PubMed]
Free PMC Article
20.

Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.

Kotsopoulos J, Metcalfe K, Alston J, Nikitina D, Ginsburg O, Eisen A, Demsky R, Akbari M, Zbuk K, Narod SA.

BMC Cancer. 2014 Mar 25;14:221. doi: 10.1186/1471-2407-14-221.

PMID:
24667084
[PubMed - in process]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk